Growing fund sizes in certain Asian markets are redefining what constitutes a middle-market GP. Are these managers evolving alongside the opportunity set or careering dangerously outside of their sweet spot?
They call it the “Hillhouse effect.” Last year, Hillhouse Capital raised $10.6 billion for a fund that is generally seen as a broad China play – it will back domestic companies with growth potential...
Meten International Education Group, a Chinese online-to-offline (O2O) English language training provider that mainly caters to adult students, has filed for a US IPO. DG Capital is the primary PE investor in the company.
VisVires New Protein, a Singapore-based VC firm specializing in food technology, has launched its second fund with a target of $150 million. Fund I closed at $40 million in 2016.
Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
SBI Investment, the VC arm of Japan’s SBI Holdings, has joined a JPY3.8 billion $35 million Series B round for Pixie Dust Technologies, a local company developing novel uses for ultrasonic waves.